흑색종 연구 항체 | BRAF, PD-1, CTLA-4 타겟 항체

홈 > 추천 제품 > Oncology Research > 흑색종

960 개의 제품 검색 결과 "흑색종"

옵션+

옵션

확인

제품 유형

0 선택됨

Antibodies (298)

Stable Cell Lines (1)

Proteins (75)

Biosimilars (1)

Assay Kit (419)

Research Biosimilar (157)
발현 시스템

0 선택됨

Mammalian Cells (186)

HEK293T (1)

E. coli (35)
타겟

0 선택됨

TRP-1 & CD3e (1)

S100P (1)

CD223/LAG3 & CD152/CTLA4 (1)

S100A10 (4)

Lintuzumab (1)

CD274/PD-L1 & CD47/MER6 (1)

CD274/PD-L1 & SLT-Ia (1)

CD80/B7-1 (20)

Oxelumab (1)

RBD (Omicron/BA.4/BA.5) (1)

CD278/ICOS (1)

Itolizumab (1)

TPP15 (1)

Anetumab (1)

Zanolimumab (1)

Blosozumab (1)

Lacnotuzumab (1)

Iscalimab (1)

Olaratumab (1)

Glycoprotein (5)

PMEL17/ME20M (9)

Protein A (1)

Tisotumab (1)

RBD (Kappa) (1)

Ramucirumab (1)

Nesvacumab (1)

Pembrolizumab (3)

mitF/aspF1 (1)

Milatuzumab (1)

Avelumab (3)

Befovacimab (1)

Casirivimab (1)

Bimagrumab (1)

gC/Envelope glycoprotein C (1)

Utomilumab (1)

Gevokizumab (1)

Tezepelumab (1)

Teprotumumab (1)

IL6 (1)

Bevacizumab (3)

SARS-CoV-2 Neutralization Antibody (3)

Ivuxolimab (1)

PDL1 & VEGF (1)

Panitumumab (3)

Ixekizumab (1)

Siltuximab (3)

Suvizumab (1)

CD47/MER6 & PDCD1 / PD-1 & CD137/4-1BB/TNFRSF9 (1)

Ibritumomab (1)

Ieramilimab (1)

CD274/PD-L1 & VEGFA (1)

TYRP1 (3)

CD19 & PD-L1 & CD3E & CD137 (1)

S100A9 (4)

Asp f 1/mitF (1)

CD274/PD-L1 & CD134/OX40 (1)

CD274/PD-L1 & CD28 & CD152/CTLA4 (1)

CD47/MER6 & CD274/PD-L1 (2)

S100A16 (1)

HLA-A2-peptide (TDQVPFSV) Complex (1)

Mosunetuzumab (1)

TPP17 (1)

Conatumumab (1)

Romosozumab (1)

TYR (1)

Romiplostim (2)

Tovetumab (1)

M/Matrix protein (2)

CD3E (1)

Belantamab (1)

PD-L1 / VEGF-A (1)

Certolizumab (2)

Enoblituzumab (1)

Cabiralizumab (1)

Gremubamab (1)

Human β Amyloid (1-42) (1)

RBD (Delta Plus) (1)

Spike glycoprotein (RBD) (1)

Vanucizumab (1)

Sintilimab (1)

Glycoprotein G (2)

Durvalumab (3)

CD80&IL2 (1)

Concizumab (1)

Imdevimab (1)

CD117/KIT (24)

Rolinsatamab (1)

gC/UL44 (1)

Magrolimab (1)

CD20/MS4A1 (3)

Etanercept (3)

Brolucizumab (1)

RBD (Omicron/BA.5) (3)

Pogalizumab (1)

Serclutamab (1)

Remtolumab (1)

Clazakizumab (1)

EGFR & CD3E & PD-L1 & 4-1BB (1)

CD366/TIM-3 & CD274/PD-L1 (1)

TRP-1 & CD47/MER6 (1)

CD274/PD-L1 & CD279/PD-1 (1)

Oleclumab (1)

IDO1 (2)

CD366/TIM-3 & CD279/PD-1 (2)

Sarilumab (2)

CD152/CTLA4 & CD279/PD-1 (1)

HLA-A2-peptide (ITDQVPFSV) Complex (4)

Secukinumab (2)

Imlifidase (5)

Olokizumab (1)

Foravirumab (1)

CD47/MER6 & CD274/PD-L1/B7-H1 (2)

Ocaratuzumab (1)

Elotuzumab (1)

Cusatuzumab (1)

TPP47 (1)

Drozitumab (1)

Ontamalimab (1)

Eldelumab (1)

Sacituzumab (1)

Eculizumab (3)

Varlilumab (1)

Tirzepatide (2)

gp100 peptide-HLA Complex (1)

Teclistamab (1)

Mirzotamab (1)

CD223 (1)

Emactuzumab (1)

M1R (5)

Human β Amyloid (1-40) (1)

Imalumab (1)

Semaglutide (2)

Ascrinvacumab (1)

TFF3 (1)

Tislelizumab (1)

Disitamab (1)

Pacmilimab (1)

TDP2 (1)

Marstacimab (1)

Daratumumab (3)

gD/US6 (1)

Basiliximab (1)

Elezanumab (1)

Apamistamab (1)

Ranibizumab (3)

NP/Nucleoprotein (3)

Tavolimab (1)

BRAF/B-Raf (5)

Mavezelimab (1)

CD137/4-1BB & CD274/PD-L1 (3)

TRP-1 & CD134/OX40 (1)

CD274/PD-L1 & TGFBR2/TGFR-2 (1)

CD80/B7-1 & CD86/B7-2 (2)

S100A11 (2)

HLA-A2-peptide (YLEPGPVT) Complex (4)

Calprotectin (S100A8/9) (3)

Lirilumab (1)

CTLA4 & PD1 (2)

Tesidolumab (1)

Sirukumab (1)

Rafivirumab (1)

cAMP (1)

RBD (WT) (1)

Vorsetuzumab (1)

G/Major surface glycoprotein G (1)

Lexatumumab (1)

Mirikizumab (2)

PDL1 (6)

Aflibercept (1)

Ipilimumab (2)

GP/Envelope glycoprotein (4)

T3E (1)

Golimumab (3)

Omburtamab (1)

TAU pT181 (1)

Evolocumab (1)

EPO/Erythropoietin (1)

Lupartumab (1)

Toripalimab (1)

Exenatide acetate (2)

Pertuzumab (3)

CD137/4-1BB/TNFRSF9& CD274/PD-L1/B7-H1 (1)

Denosumab (3)

US8/gE (1)

Sibrotuzumab (1)

Fluorescein & CD274/PD-L1 (1)

Camidanlumab (1)

Mazdutide (2)

RBD (6)

Varisacumab (1)

RBD (Omicron/JN.1) (1)

HLA-A2-peptide (KTWGQYWQV) Complex (2)

Favezelimab (1)

CD86/B7-2 (26)

CD152/CTLA4 & CD274/PD-L1 (1)

Zampilimab (1)

NRAS (2)

CD175/Tn (10)

S100A6 (1)

Omalizumab (2)

FLT1/VEGFR1 & CD274/PD-L1 (1)

RBD (Omicron/KP.2) (1)

Tibulizumab (1)

Ziltivekimab (1)

VASH2/Vasohibin-2 (1)

Carlumab (1)

RBD (Alpha) (1)

N/Nucleoprotein (1)

Tigatuzumab (1)

Glembatumumab (1)

Lenzilumab (1)

Semorinemab (1)

Talacotuzumab (1)

S100A5 (4)

Tremelimumab (1)

gG/US4 (2)

T-cell surface antigen T3/Leu-4 epsilon chain (1)

Pasotuxizumab (1)

TIGIT & CD274/PD-L1 (1)

Cixutumumab (1)

H3L (3)

TAU pT217 (1)

Andecaliximab (1)

Alirocumab (1)

Cinpanemab (1)

CD274/PD-L1 & CD28 (1)

TYR/Tyrosinase (2)

Trastuzumab (2)

Nirsevimab (1)

CD47/MER6 & PDCD1 / PD-1 / CD279 (1)

Obinutuzumab (2)

Cetuximab (3)

Ifabotuzumab (1)

CD366/HAVCR2/TIM-3 (4)

Spike glycoprotein E2 (2)

Simlukafusp Alfa (1)

LAG3 & PD-1 (1)

Daclizumab (1)

Enfortumab (1)

Emibetuzumab (1)

RBD (Delta) (3)

CD274/PD-L1 & CD137/TNFRSF9 (1)

S100A12 (1)

S100A14 (1)

CD274/PD-L1 (81)

Anifrolumab (1)

S100a15a (1)

CD152/CTLA4 & CD134/OX40 (1)

Rituximab (1)

Spike glycoprotein (10)

Crizanlizumab (1)

CD340/ERBB2 (1)

Codrituzumab (1)

Tanezumab (1)

Vunakizumab (1)

Tosatoxumab (1)

SOX10 (3)

RBD (Beta) (1)

Meplazumab (1)

Balstilimab (1)

Namilumab (1)

Dilpacimab (1)

Tilavonemab (1)

Natalizumab (2)

S100A8 (3)

Vibecotamab (1)

Zalifrelimab (1)

gB/Envelope glycoprotein B (1)

T-cell surface glycoprotein CD3 epsilon chain (1)

Rosopatamab (2)

Infliximab (2)

Frovocimab (1)

Dalotuzumab (1)

E8L (5)

S100A2 (1)

Depatuxizumab (1)

Retatrutide (1)

Zanidatamab (1)

Palivizumab (3)

KITLG/SCF (1)

Afutuzumab (1)

sCD14 (1)

CD366/TIM-3 (34)

Spike glycoprotein E1 (2)

S100A13 (1)

S100A4 (3)

CD274/PD-L1 & CD152/CTLA4 (1)

Indatuximab (1)

S100B (9)

CD223/LAG3 (41)

CD279/PD-1 & CD274/PD-L1 (1)

CD137/4-1BB & CD274/PD-L1 & ROR1 & CD3 (1)

S100A1 (2)

Vofatamab (1)

CD223/LAG3 & CD279/PD-1 (4)

Abatacept (1)

Ibalizumab (1)

Ianalumab (1)

Tocilizumab (3)

Spike Protein (Trimer) (2)

Dupilumab (3)

Inclacumab (1)

IL1RL1/ST2 (1)

VSIR/VISTA & CD274/PD-L1 (1)

Cergutuzumab (1)

cGMP (1)

Lorvotuzumab (1)

RBD (Gamma) (1)

MITF (1)

Cetrelimab (1)

DCT (2)

Otilimab (1)

Navicixizumab (1)

VEGFA & B7-H1 / PD-L1 / CD274 (1)

Zagotenemab (1)

gE/Envelope glycoprotein E (1)

Tarextumab (1)

Lodelcizumab (1)

PD-L1 & VEGF (1)

Figitumumab (1)

A35R (5)

Farletuzumab (1)

Ustekinumab (3)

CD79B (2)

Losatuxizumab (1)

Afasevikumab (1)

β-D-Glucan (1)

Suptavumab (1)

B7-H1 / PD-L1 / CD274 & CD3E (1)

Epcoritamab (1)

F/Fusion glycoprotein F0 (5)

Letolizumab (1)

dsRNA (1)

CD152/CTLA4 (86)

CD274/PD-L1 & TGFBR2 (1)

CD279/PD-1 & CD152/CTLA4 (4)

CD274/PD-L1 & CD3E (1)

p-Tyr (1)

Icrucumab (1)

ATP7B (1)

Benufutamab (1)

Amatuximab (1)

Tregalizumab (1)

PD-L1 & TGF-Beta (1)

NP/Nucleocapsid (5)

dsDNA (1)

Astegolimab (1)

Adalimumab (3)

Tiragolumab (2)

Labetuzumab (1)

Obiltoxaximab (1)

BSA (1)

RBD (E484K) (1)

Alacizumab (1)

Faricimab (1)

Nivolumab (3)

Atezolizumab (3)

Sotrovimab (1)

MLANA (4)

Edrecolomab (1)

gD/Envelope glycoprotein D (1)

Urelumab (1)

Canakinumab (1)

LAG-3 & PD-1 (1)

Ganitumab (1)

A29L (6)

Mirvetuximab (1)

B6R/SL-159 (1)

CD274/PD-L1/B7-H1 (5)

Necitumumab (1)

Bimekizumab (1)

Zenocutuzumab (1)

Glofitamab (1)

Guselkumab (3)
종

0 선택됨

Cat (1)

Mouse (27)

Canis lupus familiaris (1)

Rat (1)

Neosartorya fumigata (1)

Tupaia chinensis (12)

Mus musculus (Mouse) (7)

Canis lupus familiaris (Dog) (8)

Homo sapiens (Human) (7)

Dog (3)

Human (178)

Felis catus (Cat) (9)
응용 분야

0 선택됨

IP (2)

SDS-PAGE (75)

Bioactivity: FACS (1)

Functional assay (158)

in vitro PD-L1 blockade (3)

면역원 (75)

Research in vivo (158)

IHC-F (3)

FACS (5)

IF (8)

Bioactivity testing in progress (31)

Research in vivo (4)

Functional assay (6)

Neutralization (2)

Blocking (2)

in vivo CTLA-4 neutralization (2)

ELISA (844)

GICA (2)

in vivo (2)

in vivo intra-tumoral regulatory T cell depletion (2)

in vivo blockade (2)

Neut (1)

FCM (152)

IHC (84)

FuncS (18)

Inhib (1)

WB (165)

IFA (4)

SPR (4)

Bioactivity: FACS (153)

in vivo PD-L1 blockade (3)
반응성

0 선택됨

Capra hircus (1)

Oryzias latipes (1)

Danio rerio (1)

Xenopus laevis (1)

Macaca mulatta (1)

Drosophila grimshawi (1)

Broad-Spectrum (1)

Bovine (1)

Rat (16)

Neosartorya fumigata (1)

Drosophila willistoni (1)

Homo sapiens (Human) (4)

Monkey (5)

Cat (1)

Kirsten murine sarcoma virus (1)

Kryptolebias marmoratus (1)

Avian retrovirus IC10 (1)

Limanda limanda (1)

Avian rous-associated virus type 1 (1)

Carassius auratus (1)

Chicken (4)

Tupaia chinensis (4)

Mesocricetus auratus (1)

Bos taurus (8)

Coturnix japonica (1)

Cavia porcellus (1)

Pig (6)

Mouse (78)

Cynomolgus monkey (1)

Dog (13)

Human (198)

Callithrix jacchus (1)

Monodelphis domestica (1)

Oryctolagus cuniculus (4)

Pongo abelii (2)

Cyprinus carpio (1)

B7-H1 / PD-L1 / CD274 (1)

Rhesus macaque (1)

Mus musculus (Mouse) (1)
숙주 종

0 선택됨

Chimeric (5)

Rat (14)

Humanized (34)

Alpaca (6)

HEK293T (1)

Human (157)

Dog (2)

Mouse (164)

Armenian Hamster (5)

Rabbit (61)
클론성

0 선택됨

Polyclonal (53)

Monoclonal (398)
접합체

0 선택됨

PE (28)

FITC (28)

APC (28)

PerCP (28)

Unconjugated (301)

재조합 단백질

항체

어세이 키트

960 개의 제품 검색 결과 "흑색종"

Conatumumab ELISA Kit (DT348028)

샘플 유형

민감도

범위

Drozitumab ELISA Kit (DT348038)

샘플 유형

민감도

범위

Lexatumumab ELISA Kit (DT348048)

샘플 유형

민감도

범위

Tigatuzumab ELISA Kit (DT348058)

샘플 유형

민감도

범위

Faricimab ELISA Kit (DT073018)

샘플 유형

민감도

범위

Nesvacumab ELISA Kit (DT073028)

샘플 유형

민감도

범위

Vanucizumab ELISA Kit (DT073038)

샘플 유형

민감도

범위

Lupartumab ELISA Kit (DF831018)

샘플 유형

민감도

범위

Depatuxizumab ELISA Kit (DF004018)

샘플 유형

민감도

범위

Losatuxizumab ELISA Kit (DF004028)

샘플 유형

민감도

범위

빠른 접근

문의하기